Prognostic value of nuclear morphometry in myxoid liposarcoma

Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and ap...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science Vol. 114; no. 5; pp. 2178 - 2188
Main Authors: Kawaguchi, Kengo, Kohashi, Kenichi, Iwasaki, Takeshi, Yamamoto, Takeo, Ishihara, Shin, Toda, Yu, Yamamoto, Hidetaka, Nakashima, Yasuharu, Oda, Yoshinao
Format: Journal Article
Language:English
Published: England John Wiley & Sons, Inc 01-05-2023
John Wiley and Sons Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and applied two established grading systems to evaluate nuclear atypia (namely, the World Health Organization/International Society of Urological Pathology and the Fuhrman grading in renal cell carcinoma) in 64 MLS cases. Detailed software‐based assessments of the morphology and the cellularity were performed. DNA mutation analysis, comprehensive mRNA expression analysis, and immunohistochemistry were also performed. Our findings revealed that the high–nuclear‐grade group according to the modified Fuhrman grading system exhibited a significantly poor disease‐free survival (hazard ratio: 4.43; 95% confidence interval: 0.9‐22.6; p = 0.047). On the other hand, the cellularity was significantly higher in the modified Fuhrman high‐grade group (p = 0.010 at the percentage of the hypercellular area; p = 0.003 at the maximum cell density) but did not qualify per se as a poor prognostic factor in the survival analyses. Furthermore, the modified Fuhrman high‐grade group significantly expressed the cell cycle–related genes (such as FOXM1, PLK1, and CDK1). In conclusion, our analyses suggest that an evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the MLS prognosis. The evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the myxoid liposarcoma (MLS) prognosis. Modified Fuhrman grading is useful for the morphology evaluation. The high–nuclear‐grade group significantly expressed the cell cycle–related genes (such as FOXM1, PLK1, and CDK1).
AbstractList Myxoid liposarcoma (MLS) accounts for 20%-30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and applied two established grading systems to evaluate nuclear atypia (namely, the World Health Organization/International Society of Urological Pathology and the Fuhrman grading in renal cell carcinoma) in 64 MLS cases. Detailed software-based assessments of the morphology and the cellularity were performed. DNA mutation analysis, comprehensive mRNA expression analysis, and immunohistochemistry were also performed. Our findings revealed that the high–nuclear-grade group according to the modified Fuhrman grading system exhibited a significantly poor disease-free survival (hazard ratio: 4.43; 95% confidence interval: 0.9-22.6; p = 0.047). On the other hand, the cellularity was significantly higher in the modified Fuhrman high-grade group (p = 0.010 at the percentage of the hypercellular area; p = 0.003 at the maximum cell density) but did not qualify per se as a poor prognostic factor in the survival analyses. Furthermore, the modified Fuhrman high-grade group significantly expressed the cell cycle–related genes (such as FOXM1, PLK1, and CDK1). In conclusion, our analyses suggest that an evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the MLS prognosis.
Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and applied two established grading systems to evaluate nuclear atypia (namely, the World Health Organization/International Society of Urological Pathology and the Fuhrman grading in renal cell carcinoma) in 64 MLS cases. Detailed software‐based assessments of the morphology and the cellularity were performed. DNA mutation analysis, comprehensive mRNA expression analysis, and immunohistochemistry were also performed. Our findings revealed that the high–nuclear‐grade group according to the modified Fuhrman grading system exhibited a significantly poor disease‐free survival (hazard ratio: 4.43; 95% confidence interval: 0.9‐22.6; p = 0.047). On the other hand, the cellularity was significantly higher in the modified Fuhrman high‐grade group (p = 0.010 at the percentage of the hypercellular area; p = 0.003 at the maximum cell density) but did not qualify per se as a poor prognostic factor in the survival analyses. Furthermore, the modified Fuhrman high‐grade group significantly expressed the cell cycle–related genes (such as FOXM1, PLK1, and CDK1). In conclusion, our analyses suggest that an evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the MLS prognosis. The evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the myxoid liposarcoma (MLS) prognosis. Modified Fuhrman grading is useful for the morphology evaluation. The high–nuclear‐grade group significantly expressed the cell cycle–related genes (such as FOXM1, PLK1, and CDK1).
Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and applied two established grading systems to evaluate nuclear atypia (namely, the World Health Organization/International Society of Urological Pathology and the Fuhrman grading in renal cell carcinoma) in 64 MLS cases. Detailed software‐based assessments of the morphology and the cellularity were performed. DNA mutation analysis, comprehensive mRNA expression analysis, and immunohistochemistry were also performed. Our findings revealed that the high–nuclear‐grade group according to the modified Fuhrman grading system exhibited a significantly poor disease‐free survival (hazard ratio: 4.43; 95% confidence interval: 0.9‐22.6; p  = 0.047). On the other hand, the cellularity was significantly higher in the modified Fuhrman high‐grade group ( p  = 0.010 at the percentage of the hypercellular area; p  = 0.003 at the maximum cell density) but did not qualify per se as a poor prognostic factor in the survival analyses. Furthermore, the modified Fuhrman high‐grade group significantly expressed the cell cycle–related genes (such as FOXM1 , PLK1 , and CDK1 ). In conclusion, our analyses suggest that an evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the MLS prognosis.
Myxoid liposarcoma (MLS) accounts for 20%-30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and applied two established grading systems to evaluate nuclear atypia (namely, the World Health Organization/International Society of Urological Pathology and the Fuhrman grading in renal cell carcinoma) in 64 MLS cases. Detailed software-based assessments of the morphology and the cellularity were performed. DNA mutation analysis, comprehensive mRNA expression analysis, and immunohistochemistry were also performed. Our findings revealed that the high-nuclear-grade group according to the modified Fuhrman grading system exhibited a significantly poor disease-free survival (hazard ratio: 4.43; 95% confidence interval: 0.9-22.6; p = 0.047). On the other hand, the cellularity was significantly higher in the modified Fuhrman high-grade group (p = 0.010 at the percentage of the hypercellular area; p = 0.003 at the maximum cell density) but did not qualify per se as a poor prognostic factor in the survival analyses. Furthermore, the modified Fuhrman high-grade group significantly expressed the cell cycle-related genes (such as FOXM1, PLK1, and CDK1). In conclusion, our analyses suggest that an evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the MLS prognosis.
Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However, the RCC assessment criteria are vaguely defined and, therefore, are inconsistently employed by pathologists. In this study, we modified and applied two established grading systems to evaluate nuclear atypia (namely, the World Health Organization/International Society of Urological Pathology and the Fuhrman grading in renal cell carcinoma) in 64 MLS cases. Detailed software‐based assessments of the morphology and the cellularity were performed. DNA mutation analysis, comprehensive mRNA expression analysis, and immunohistochemistry were also performed. Our findings revealed that the high–nuclear‐grade group according to the modified Fuhrman grading system exhibited a significantly poor disease‐free survival (hazard ratio: 4.43; 95% confidence interval: 0.9‐22.6; p  = 0.047). On the other hand, the cellularity was significantly higher in the modified Fuhrman high‐grade group ( p  = 0.010 at the percentage of the hypercellular area; p  = 0.003 at the maximum cell density) but did not qualify per se as a poor prognostic factor in the survival analyses. Furthermore, the modified Fuhrman high‐grade group significantly expressed the cell cycle–related genes (such as FOXM1 , PLK1 , and CDK1 ). In conclusion, our analyses suggest that an evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the MLS prognosis. The evaluation focusing on nuclear morphology (rather than on cellular density) can be more reliable in predicting the myxoid liposarcoma (MLS) prognosis. Modified Fuhrman grading is useful for the morphology evaluation. The high–nuclear‐grade group significantly expressed the cell cycle–related genes (such as FOXM1, PLK1, and CDK1 ).
Author Nakashima, Yasuharu
Oda, Yoshinao
Iwasaki, Takeshi
Yamamoto, Hidetaka
Yamamoto, Takeo
Ishihara, Shin
Kawaguchi, Kengo
Kohashi, Kenichi
Toda, Yu
AuthorAffiliation 1 Department of Anatomic Pathology, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
2 Department of Orthopaedic Surgery, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
AuthorAffiliation_xml – name: 2 Department of Orthopaedic Surgery, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
– name: 1 Department of Anatomic Pathology, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
Author_xml – sequence: 1
  givenname: Kengo
  surname: Kawaguchi
  fullname: Kawaguchi, Kengo
  organization: Kyushu University
– sequence: 2
  givenname: Kenichi
  surname: Kohashi
  fullname: Kohashi, Kenichi
  organization: Kyushu University
– sequence: 3
  givenname: Takeshi
  surname: Iwasaki
  fullname: Iwasaki, Takeshi
  organization: Kyushu University
– sequence: 4
  givenname: Takeo
  surname: Yamamoto
  fullname: Yamamoto, Takeo
  organization: Kyushu University
– sequence: 5
  givenname: Shin
  surname: Ishihara
  fullname: Ishihara, Shin
  organization: Kyushu University
– sequence: 6
  givenname: Yu
  surname: Toda
  fullname: Toda, Yu
  organization: Kyushu University
– sequence: 7
  givenname: Hidetaka
  surname: Yamamoto
  fullname: Yamamoto, Hidetaka
  organization: Kyushu University
– sequence: 8
  givenname: Yasuharu
  surname: Nakashima
  fullname: Nakashima, Yasuharu
  organization: Kyushu University
– sequence: 9
  givenname: Yoshinao
  orcidid: 0000-0001-9636-1182
  surname: Oda
  fullname: Oda, Yoshinao
  email: oda.yoshinao.389@m.kyushu‐u.ac.jp
  organization: Kyushu University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36661410$$D View this record in MEDLINE/PubMed
BookMark eNp1kctKAzEUhoMoXqoLX0AG3Oii9eQymclCpBRvICio65BmMjUyk9SkU-3bG1sVFczmhOTj4z_8O2jdeWcQ2scwwOmcaBUHOC-IWEPbmDLRLwD4-vJe9AVQsoV2YnwGoJwJtom2KOccMwzb6PQu-InzcWZ1NldNZzJfZ67TjVEha32YPvnWzMIisy5rF2_eVlljpz6qoH2rdtFGrZpo9j5nDz1enD-Mrvo3t5fXo-FNX-cfcbQmoEhVGcCFwuOaQskMVEJxRqkulFJQpZccGNC8qDgrxpxqTEohoKa0oj10tvJOu3FrKm3cLKhGToNtVVhIr6z8_ePsk5z4ucSAc1aKMhmOPg3Bv3QmzmRrozZNo5zxXZSk4CVhJC9JQg__oM--Cy7tJ0mZkjOBeZ6o4xWlg48xmPo7DQb50YpMrchlK4k9-Bn_m_yqIQEnK-DVNmbxv0mOhvcr5TuyvJgj
CitedBy_id crossref_primary_10_1007_s00428_023_03631_5
crossref_primary_10_3390_cancers16112026
crossref_primary_10_1136_jcp_2023_208963
crossref_primary_10_1007_s00428_024_03796_7
crossref_primary_10_1136_jcp_2023_208814
Cites_doi 10.1038/onc.2016.157
10.1002/cncr.31176
10.1038/75556
10.1097/00000478-198210000-00007
10.1038/s41379-021-00972-x
10.1039/C5MB00663E
10.1038/ncb1217
10.1038/s41374-018-0057-0
10.15252/emmm.201809889
10.1245/s10434-006-9043-7
10.3390/ijms19020608
10.1038/modpathol.2011.148
10.1038/modpathol.2011.219
10.18632/oncotarget.10373
10.1007/s13277-015-4351-9
10.1186/1747-1028-5-11
10.1093/nar/gkw937
10.1155/2011/538085
10.1007/978-1-4899-8032-8_25
10.1148/radiol.2282011860
10.1111/j.0006-341X.2000.00337.x
10.1002/cncr.27847
10.1038/nprot.2012.004
10.1038/bjc.2012.424
10.1093/bioinformatics/btp616
10.1038/nrc3219
10.1186/1747-1028-3-4
10.1002/(SICI)1097-0142(19960415)77:8<1450::AID-CNCR5>3.0.CO;2-G
10.1038/s41598-019-56247-8
10.1186/1756-9966-33-33
10.1111/cas.15256
10.1038/s41598-017-17204-5
10.1186/s12964-018-0266-6
10.1159/000508780
10.1002/cncr.22720
10.1007/s00432-020-03438-w
10.3390/uro1010002
10.1515/BC.2007.159
10.1038/s41467-022-30847-x
10.1002/path.1848
10.1002/cjp2.16
10.1245/s10434-011-2127-z
10.11613/BM.2012.031
ContentType Journal Article
Copyright 2023 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
2023. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2023 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
– notice: 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
– notice: 2023. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
8FE
8FH
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
HCIFZ
LK8
M7P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1111/cas.15729
DatabaseName Wiley Open Access
Wiley Free Archive
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Databases
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central
ProQuest Central Student
SciTech Premium Collection
Biological Sciences
Biological Science Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest Biological Science Collection
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
Biological Science Database
ProQuest SciTech Collection
ProQuest Central China
ProQuest Central
ProQuest One Academic UKI Edition
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest One Academic
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

CrossRef
MEDLINE

Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Kawaguchi et al
EISSN 1349-7006
EndPage 2188
ExternalDocumentID 10_1111_cas_15729
36661410
CAS15729
Genre researchArticle
Journal Article
GrantInformation_xml – fundername: Japan Society for the Promotion of Science
  funderid: 19H03444; 21K06887; 21K20805
– fundername: Japan Society for the Promotion of Science
  grantid: 21K06887
– fundername: Japan Society for the Promotion of Science
  grantid: 21K20805
– fundername: Japan Society for the Promotion of Science
  grantid: 19H03444
– fundername: ;
  grantid: 19H03444; 21K06887; 21K20805
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1OC
24P
29B
2WC
31~
36B
3O-
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52W
52X
53G
5GY
5HH
5LA
5VS
66C
7.U
702
7PT
8-0
8-1
8-3
8-4
8-5
8FE
8FH
8UM
930
A01
A03
AAHHS
AAZKR
ABCQN
ABEML
ACCFJ
ACSCC
ACXQS
ADBBV
ADKYN
ADZMN
ADZOD
AEEZP
AENEX
AEQDE
AFBPY
AFEBI
AFFNX
AFKRA
AFPKN
AFZJQ
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
BAWUL
BBNVY
BCNDV
BENPR
BFHJK
BHPHI
BY8
CAG
CCPQU
COF
CS3
D-6
D-7
D-E
D-F
DIK
DR2
DU5
E3Z
EBS
EJD
EMB
EMOBN
EX3
F00
F01
F04
F5P
FIJ
GODZA
GROUPED_DOAJ
HCIFZ
HF~
HOLLA
HYE
HZI
HZ~
IAO
IHR
IPNFZ
IX1
J0M
K.9
K48
KQ8
LC2
LC3
LH4
LK8
LP6
LP7
LW6
M7P
MK4
N04
N05
N9A
O9-
OIG
OK1
OVD
P2P
P2X
P2Z
P4B
P4D
PIMPY
PROAC
Q11
ROL
RPM
RX1
SJN
SUPJJ
SV3
TEORI
UB1
W8V
WIN
WOW
WQJ
WRC
WXI
X7M
XG1
ZXP
~IA
~WT
CGR
CUY
CVF
ECM
EIF
ITC
NPM
AAYXX
CITATION
ABUWG
AZQEC
DWQXO
GNUQQ
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c5349-cc20a2dde017a1bf3084e0d9a6433c7aaa0d84e5040357d647b63c128990f33d3
IEDL.DBID RPM
ISSN 1347-9032
IngestDate Tue Sep 17 21:30:56 EDT 2024
Fri Oct 25 05:57:33 EDT 2024
Thu Oct 10 22:42:14 EDT 2024
Fri Nov 22 02:47:33 EST 2024
Sat Sep 28 08:13:22 EDT 2024
Sat Aug 24 00:51:22 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords cell cycle-related gene
morphometry
myxoid liposarcoma
round cell component
nuclear atypia
Language English
License Attribution-NonCommercial
2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5349-cc20a2dde017a1bf3084e0d9a6433c7aaa0d84e5040357d647b63c128990f33d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-9636-1182
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154898/
PMID 36661410
PQID 2808449165
PQPubID 4378882
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10154898
proquest_miscellaneous_2768242582
proquest_journals_2808449165
crossref_primary_10_1111_cas_15729
pubmed_primary_36661410
wiley_primary_10_1111_cas_15729_CAS15729
PublicationCentury 2000
PublicationDate May 2023
PublicationDateYYYYMMDD 2023-05-01
PublicationDate_xml – month: 05
  year: 2023
  text: May 2023
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Tokyo
– name: Hoboken
PublicationTitle Cancer science
PublicationTitleAlternate Cancer Sci
PublicationYear 2023
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
References 2015; 1
2017; 7
2019; 9
2007; 388
2020; 64
2000; 25
2019; 11
2021; 147
2018; 124
2017; 45
2012; 19
2008; 3
2021; 1
2012; 12
2007; 109
2016; 37
2012; 107
2016; 35
2007; 14
2022; 113
2016; 12
2014; 773
1996; 77
2011; 2011
2021; 35
2018; 19
2016; 7
2003; 228
2010; 26
2013; 119
2022
2000; 56
2020
1982; 6
2019
2005; 207
2022; 13
2005; 7
2012; 25
2012; 7
2018; 98
2010; 5
2012; 22
2018; 16
2014; 33
e_1_2_10_23_1
e_1_2_10_46_1
e_1_2_10_24_1
e_1_2_10_45_1
e_1_2_10_21_1
e_1_2_10_44_1
e_1_2_10_22_1
e_1_2_10_43_1
e_1_2_10_42_1
e_1_2_10_20_1
e_1_2_10_41_1
e_1_2_10_40_1
Goldblum J (e_1_2_10_7_1) 2019
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_16_1
e_1_2_10_39_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_38_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_37_1
e_1_2_10_15_1
e_1_2_10_36_1
e_1_2_10_12_1
e_1_2_10_35_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_34_1
e_1_2_10_10_1
e_1_2_10_33_1
e_1_2_10_11_1
e_1_2_10_32_1
e_1_2_10_31_1
e_1_2_10_30_1
WHO Classification of Tumours Editorial Board (e_1_2_10_6_1) 2020
WHO Classification of Tumours Editorial Board (e_1_2_10_18_1) 2022
e_1_2_10_29_1
e_1_2_10_27_1
e_1_2_10_28_1
e_1_2_10_25_1
e_1_2_10_26_1
e_1_2_10_47_1
References_xml – volume: 25
  start-page: 212
  year: 2012
  end-page: 221
  article-title: Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma
  publication-title: Mod Pathol
– volume: 35
  start-page: 6177
  year: 2016
  end-page: 6188
  article-title: miR‐135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma
  publication-title: Oncogene
– volume: 6
  start-page: 655
  year: 1982
  end-page: 663
  article-title: Prognostic significance of morphologic parameters in renal cell carcinoma
  publication-title: Am J Surg Pathol
– volume: 25
  start-page: 25
  year: 2000
  end-page: 29
  article-title: Gene ontology: tool for the unification of biology
  publication-title: Nat Genet
– volume: 124
  start-page: 1179
  year: 2018
  end-page: 1187
  article-title: Presentation and outcome of frequent and rare sarcoma histologic subtypes: a study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers
  publication-title: Cancer
– volume: 16
  start-page: 57
  year: 2018
  article-title: Regulation of the master regulator FOXM1 in cancer
  publication-title: Cell Commun Signal
– volume: 12
  start-page: 477
  year: 2016
  end-page: 479
  article-title: ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization
  publication-title: Mol Biosyst
– volume: 7
  start-page: 126
  year: 2005
  end-page: 136
  article-title: FoxM1 is required for execution of the mitotic programme and chromosome stability
  publication-title: Nat Cell Biol
– volume: 56
  start-page: 337
  issue: 2
  year: 2000
  end-page: 344
  article-title: Time‐dependent ROC curves for censored survival data and a diagnostic marker
  publication-title: Biometrics
– volume: 7
  start-page: 670
  year: 2012
  end-page: 685
  article-title: Topological analysis and interactive visualization of biological networks and protein structures
  publication-title: Nat Protoc
– volume: 19
  start-page: 608
  year: 2018
  article-title: Presence of TERT promoter mutations is a secondary event and associates with elongated telomere length in myxoid liposarcomas
  publication-title: Int J Mol Sci
– volume: 19
  start-page: 1081
  year: 2012
  end-page: 1088
  article-title: Myxoid/round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases
  publication-title: Ann Surg Oncol
– volume: 33
  start-page: 33
  year: 2014
  article-title: TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities
  publication-title: J Exp Clin Cancer Res
– volume: 109
  start-page: 2522
  year: 2007
  end-page: 2531
  article-title: Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution
  publication-title: Cancer
– volume: 12
  start-page: 196
  year: 2012
  end-page: 209
  article-title: The nuclear envelope environment and its cancer connections
  publication-title: Nat Rev Cancer
– volume: 37
  start-page: 5213
  year: 2016
  end-page: 5223
  article-title: FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target
  publication-title: Tumour Biol
– volume: 45
  start-page: D362
  year: 2017
  end-page: D368
  article-title: The STRING database in 2017: quality‐controlled protein‐protein association networks, made broadly accessible
  publication-title: Nucleic Acids Res
– volume: 3
  start-page: 4
  year: 2008
  article-title: Self‐regulated mechanism of Plk1 localization to kinetochores: lessons from the Plk1‐PBIP1 interaction
  publication-title: Cell Div
– volume: 22
  start-page: 276
  year: 2012
  end-page: 282
  article-title: Interrater reliability: the kappa statistic
  publication-title: Biochem Med (Zagreb)
– volume: 13
  start-page: 3107
  year: 2022
  article-title: Establishment of mouse model of inherited PIGO deficiency and therapeutic potential of AAV‐based gene therapy
  publication-title: Nat Commun
– volume: 147
  start-page: 1499
  year: 2021
  end-page: 1518
  article-title: The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor
  publication-title: J Cancer Res Clin Oncol
– volume: 64
  start-page: 511
  year: 2020
  end-page: 519
  article-title: Nuclear morphology and the biology of cancer cells
  publication-title: Acta Cytol
– volume: 388
  start-page: 1257
  year: 2007
  end-page: 1274
  article-title: FOXM1, a typical proliferation‐associated transcription factor
  publication-title: Biol Chem
– volume: 1
  start-page: 2
  year: 2021
  end-page: 13
  article-title: Comparing World Health Organization/International Society of Urological Pathology Grading and Fuhrman Grading with the prognostic value of nuclear area in patients with renal cell carcinoma
  publication-title: Uro
– volume: 2011
  year: 2011
  article-title: Prognostic factors and metastatic patterns in primary myxoid/round‐cell liposarcoma
  publication-title: Sarcoma
– volume: 77
  start-page: 1450
  year: 1996
  end-page: 1458
  article-title: The clinicopathologic spectrum of myxoid and round cell liposarcoma: a study of 95 cases
  publication-title: Cancer
– volume: 7
  start-page: 49481
  year: 2016
  end-page: 49497
  article-title: Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer
  publication-title: Oncotarget
– volume: 773
  start-page: 537
  year: 2014
  end-page: 569
  article-title: Mechanisms of nuclear size regulation in model systems and cancer
  publication-title: Adv Exp Med Biol
– volume: 107
  start-page: 1766
  year: 2012
  end-page: 1775
  article-title: The FOXM1‐PLK1 axis is commonly upregulated in oesophageal adenocarcinoma
  publication-title: Br J Cancer
– volume: 35
  start-page: 640
  year: 2021
  end-page: 648
  article-title: Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation
  publication-title: Mod Pathol
– volume: 1
  start-page: 144
  year: 2015
  end-page: 159
  article-title: Cancer‐testis antigens PRAME and NY‐ESO‐1 correlate with tumour grade and poor prognosis in myxoid liposarcoma
  publication-title: J Pathol Clin Res
– volume: 9
  start-page: 19704
  year: 2019
  article-title: Prevalence of the hippo effectors YAP1/TAZ in tumors of soft tissue and bone
  publication-title: Sci Rep
– volume: 119
  start-page: 1868
  year: 2013
  end-page: 1877
  article-title: Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations
  publication-title: Cancer
– volume: 25
  start-page: 869
  year: 2012
  end-page: 876
  article-title: Semi‐quantitative immunohistochemical assay versus oncotype DX® qRT‐PCR assay for estrogen and progesterone receptors: an independent quality assurance study
  publication-title: Mod Pathol
– year: 2022
– volume: 228
  start-page: 303
  year: 2003
  end-page: 308
  article-title: Measurement of observer agreement
  publication-title: Radiology
– volume: 26
  start-page: 139
  year: 2010
  end-page: 140
  article-title: edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
  publication-title: Bioinformatics
– year: 2020
– volume: 113
  start-page: 1078
  year: 2022
  end-page: 1089
  article-title: High prevalence of TERT aberrations in myxoid liposarcoma: TERT reactivation may play a crucial role in tumorigenesis
  publication-title: Cancer Sci
– volume: 98
  start-page: 844
  year: 2018
  end-page: 855
  article-title: Principles and approaches for reproducible scoring of tissue stains in research
  publication-title: Lab Invest
– volume: 11
  year: 2019
  article-title: Requirement for YAP1 signaling in myxoid liposarcoma
  publication-title: EMBO mol Med
– volume: 5
  start-page: 11
  year: 2010
  article-title: An overview of Cdk1‐controlled targets and processes
  publication-title: Cell Div
– volume: 7
  start-page: 16878
  year: 2017
  article-title: QuPath: open source software for digital pathology image analysis
  publication-title: Sci Rep
– volume: 14
  start-page: 222
  year: 2007
  end-page: 229
  article-title: Clinicopathologic prognostic factors in myxoid liposarcoma: a retrospective study of 49 patients with long‐term follow‐up
  publication-title: Ann Surg Oncol
– year: 2019
– volume: 207
  start-page: 410
  year: 2005
  end-page: 421
  article-title: Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis
  publication-title: J Pathol
– ident: e_1_2_10_13_1
  doi: 10.1038/onc.2016.157
– ident: e_1_2_10_8_1
  doi: 10.1002/cncr.31176
– ident: e_1_2_10_27_1
  doi: 10.1038/75556
– ident: e_1_2_10_19_1
  doi: 10.1097/00000478-198210000-00007
– ident: e_1_2_10_24_1
  doi: 10.1038/s41379-021-00972-x
– ident: e_1_2_10_28_1
  doi: 10.1039/C5MB00663E
– ident: e_1_2_10_47_1
  doi: 10.1038/ncb1217
– ident: e_1_2_10_31_1
  doi: 10.1038/s41374-018-0057-0
– ident: e_1_2_10_37_1
  doi: 10.15252/emmm.201809889
– ident: e_1_2_10_14_1
  doi: 10.1245/s10434-006-9043-7
– ident: e_1_2_10_34_1
  doi: 10.3390/ijms19020608
– ident: e_1_2_10_36_1
  doi: 10.1038/modpathol.2011.148
– ident: e_1_2_10_32_1
  doi: 10.1038/modpathol.2011.219
– ident: e_1_2_10_41_1
  doi: 10.18632/oncotarget.10373
– volume-title: Enzinger and Weiss's Soft Tissue Tumors
  year: 2019
  ident: e_1_2_10_7_1
  contributor:
    fullname: Goldblum J
– ident: e_1_2_10_42_1
  doi: 10.1007/s13277-015-4351-9
– ident: e_1_2_10_45_1
  doi: 10.1186/1747-1028-5-11
– ident: e_1_2_10_29_1
  doi: 10.1093/nar/gkw937
– ident: e_1_2_10_11_1
  doi: 10.1155/2011/538085
– ident: e_1_2_10_3_1
  doi: 10.1007/978-1-4899-8032-8_25
– ident: e_1_2_10_20_1
  doi: 10.1148/radiol.2282011860
– volume-title: Soft Tissue and Bone Tumours
  year: 2020
  ident: e_1_2_10_6_1
  contributor:
    fullname: WHO Classification of Tumours Editorial Board
– ident: e_1_2_10_33_1
  doi: 10.1111/j.0006-341X.2000.00337.x
– ident: e_1_2_10_9_1
  doi: 10.1002/cncr.27847
– ident: e_1_2_10_30_1
  doi: 10.1038/nprot.2012.004
– ident: e_1_2_10_40_1
  doi: 10.1038/bjc.2012.424
– ident: e_1_2_10_26_1
  doi: 10.1093/bioinformatics/btp616
– ident: e_1_2_10_4_1
  doi: 10.1038/nrc3219
– ident: e_1_2_10_44_1
  doi: 10.1186/1747-1028-3-4
– ident: e_1_2_10_12_1
  doi: 10.1002/(SICI)1097-0142(19960415)77:8<1450::AID-CNCR5>3.0.CO;2-G
– ident: e_1_2_10_38_1
  doi: 10.1038/s41598-019-56247-8
– ident: e_1_2_10_35_1
  doi: 10.1186/1756-9966-33-33
– ident: e_1_2_10_15_1
  doi: 10.1111/cas.15256
– ident: e_1_2_10_23_1
  doi: 10.1038/s41598-017-17204-5
– ident: e_1_2_10_39_1
  doi: 10.1186/s12964-018-0266-6
– ident: e_1_2_10_2_1
  doi: 10.1159/000508780
– ident: e_1_2_10_16_1
  doi: 10.1002/cncr.22720
– ident: e_1_2_10_43_1
  doi: 10.1007/s00432-020-03438-w
– ident: e_1_2_10_5_1
  doi: 10.3390/uro1010002
– ident: e_1_2_10_46_1
  doi: 10.1515/BC.2007.159
– volume-title: Urinary and Male Genital Tumours
  year: 2022
  ident: e_1_2_10_18_1
  contributor:
    fullname: WHO Classification of Tumours Editorial Board
– ident: e_1_2_10_22_1
  doi: 10.1038/s41467-022-30847-x
– ident: e_1_2_10_17_1
  doi: 10.1002/path.1848
– ident: e_1_2_10_25_1
  doi: 10.1002/cjp2.16
– ident: e_1_2_10_10_1
  doi: 10.1245/s10434-011-2127-z
– ident: e_1_2_10_21_1
  doi: 10.11613/BM.2012.031
SSID ssj0036494
Score 2.4712303
Snippet Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However,...
Myxoid liposarcoma (MLS) accounts for 20%-30% of liposarcoma and the round cell component (RCC) is believed to be a specific poor prognostic factor. However,...
SourceID pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 2178
SubjectTerms Adult
Carcinoma, Renal Cell - pathology
Cell cycle
cell cycle–related gene
Cell density
Cyclin-dependent kinases
Cytology
DNA damage
Gene expression
Genes
Genetic testing
Humans
Immunohistochemistry
Kidney Neoplasms - pathology
Kinases
Liposarcoma
Liposarcoma, Myxoid - genetics
Lymphocytes
Medical prognosis
Morphology
Morphometry
myxoid liposarcoma
nuclear atypia
Open source software
Original
Pathology
Polo-like kinase 1
Prognosis
Proteins
Renal cell carcinoma
round cell component
Survival Analysis
Telomerase
Title Prognostic value of nuclear morphometry in myxoid liposarcoma
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.15729
https://www.ncbi.nlm.nih.gov/pubmed/36661410
https://www.proquest.com/docview/2808449165
https://search.proquest.com/docview/2768242582
https://pubmed.ncbi.nlm.nih.gov/PMC10154898
Volume 114
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-QwDLYYDogLWpZXl4eyiAOXMmnTNulxNAvaCyskQOJWpXmISrQdzTAS_HuctB2BRlz2VjVpY9lObCfOZ4ALVXJjKLWhytxuVcZ1WOYyDSNW2oiWJmbWb13c839P4s-1g8nJhrswPmlfldVV81JfNdWzz62c1Wo85ImN726nkXe0czEewQidwyFG79ZfliV5V8o24WFOWdzjCbn8HVdGLErxk23YYpkzTe7m7GeDtOZlridLfnZivRW6-QE7vftIJh2Zu7Bhmp-wddsfkO-BQ793qXPYTByOtyGtJY3DLJZzUrfI1LY2r_N3UjWkfn9rK01eqlm7QHVva7kPjzfXD9O_YV8hIVQpS_JQqZjKGFconFcyKi2jIjFU5xL9DKa4lJJqfJPiTGUp11nCy4ypyAVZ1DKm2QFsNm1jjoBYZJtNKcpN6ARtuBBGlNoYzlUsrUoDOB_YVMw6IIxiCCCQrYVnawAnAwOLfi4silggVQm6ofiP36tm1GJ3NCEb0y6xD0Y9LvgRcQCHHb9XowyCCkB8kcSqg0PI_tqCiuORsgdFCeDSC-17yovp5N4__Pr_UY5h2xWj79IhT2Dzdb40pzBa6OWZD_XPvJ5-AAUM6uo
link.rule.ids 230,315,729,782,786,866,887,27933,27934,53800,53802
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB7xkCgXoA_aFGhd1EMvYZ04iZ0jWkBUZVElQOotcvwQkUiy2mUl-PcdO8kKhLhwizJWnPjLeGbs8TcAP1XJjaHUhipzq1UZ12GZyzSMWGkjWpqYWb90ccUv_4mTU0eTkw1nYXzSviqro-auPmqqW59bOa3VaMgTG_2djCPvaOditArrqLCUDlF6NwOzLMm7YrYJD3PK4p5RyGXwuEJiUYoe5SZssMwZJ3d29qlJeuFnvkyXfOrGejt0tv3WL9iBrd7zJMed_D2smOYDbEz6vfWP4IjzXdYdiomjADektaRxdMdyRuoW8Whrcz97JFVD6seHttLkrpq2c9SUtpaf4Obs9Hp8HvbFFUKVsiQPlYqpjHFyQ5WUUWkZFYmhOpfoojDFpZRU450UlZylXGcJLzOmIhefUcuYZruw1rSN-QLE4njblCLkQido_oUwotTGcK5iaVUawOEwvsW049AohtgD8Sg8HgHsDyNf9Go0L2KBb5WgB4vP-LEUowK4XQ3ZmHaBbTBgcnGTiAP43AG17GVAOADxDMJlA0eu_VyCiHmS7QGhAH55tF9_82J8fOUvvr69l-_w7vx6clFc_L78swebrqZ9l1W5D2v3s4U5gNW5Xnzzv_l_V9P_sg
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwEB0VkFZc2tIPSEupqThwCevESez0hhZWrQoICSr1Fjn-EJFIstplpfLvO3aSFQj1ArcotuLEL2O_scdvAA5UyY2h1IYqc6tVGddhmcs0jFhpI1qamFm_dHHFL_6Ik1Mnk_N9OAvjg_ZVWR01t_VRU9342MpZrcZDnNj48nwSeaKdi_FM2_EabKDR0njw1LtRmGVJ3iW0TXiYUxb3qkIuisclE4tSZJWbMGKZm6Dc-dmH09ITrvk0ZPIhlfVz0fTNS77iLbzuGSg57upswSvTvIPReb_H_h6cgL6LvsNi4qTADWktaZzssZyTukVc2trcze9J1ZD6_m9baXJbzdoFWkxbyw_we3p6PfkR9kkWQpWyJA-ViqmMcZBD05RRaRkViaE6l0hVmOJSSqrxTorGzlKus4SXGVOR89OoZUyzj7DetI3ZAWKxz21KEXqhE6QBQhhRamM4V7G0Kg3g29DHxazT0igGHwQxKTwmAewOvV_05rQoYoFvlSCTxWfsr4rRENzuhmxMu8Q66Dg5_0nEAWx3YK1aGVAOQDyCcVXBiWw_LkHUvNj2gFIAhx7x_795MTm-8hefnt_KVxhdnkyLs58Xvz7Dpktt3wVX7sL63XxpvsDaQi_3_J_-D3wVAkE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+nuclear+morphometry+in+myxoid+liposarcoma&rft.jtitle=Cancer+science&rft.au=Kawaguchi%2C+Kengo&rft.au=Kohashi%2C+Kenichi&rft.au=Iwasaki%2C+Takeshi&rft.au=Yamamoto%2C+Takeo&rft.date=2023-05-01&rft.issn=1347-9032&rft.eissn=1349-7006&rft.volume=114&rft.issue=5&rft.spage=2178&rft.epage=2188&rft_id=info:doi/10.1111%2Fcas.15729&rft.externalDBID=10.1111%252Fcas.15729&rft.externalDocID=CAS15729
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-9032&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-9032&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-9032&client=summon